Sort
23,748 grants matching “melanoma”
Role of PI3Kgamma in Tumor Progression and Metastasis
$535,870Judith A. Varner · University Of California, San Diego · R01 · FY2025 · CA
Role of PI3Kgamma in Tumor Progression and Metastasis
$535,870Judith A. Varner · University Of California, San Diego · R01 · FY2023 · CA
TARGETING ACRAL MELANOMA BY INDUCING TERT DEGRADATION (ME190011). NEW AWARD.
$535,800The Wistar Institute Of Anatomy And Biology · · FY2020 · Defense Health Agency
The Biology and Biochemistry of Lipid Transfer Protein-Regulated Phosphoinositide Signaling
$535,709Vytas A Bankaitis · Texas A&M University Health Science Ctr · R35 · FY2025 · GM
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
$535,666Philip O. Livingston · Mabvax Therapeutics, Inc. · R42 · FY2010 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$535,638Wei R. Chen · University Of Oklahoma · R01 · FY2022 · CA
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
$535,530Jinming Gao · Ut Southwestern Medical Center · U01 · FY2018 · CA
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
$535,530Jinming Gao · Ut Southwestern Medical Center · U01 · FY2021 · CA
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
$535,530Jinming Gao · Ut Southwestern Medical Center · U01 · FY2017 · CA
Regulation of Lymphocyte Proliferation and Replicative Capacity
$535,509Richard J. Hodes · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Identifying the mechanism of anti-colorectal immunity induced by mucoinvasive colonic bacteria
$535,501Timothy Wesley Hand · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
$535,362J. Silvio Gutkind · University Of California, San Diego · R01 · FY2022 · CA
EZH2 in cancer biology and novel inhibitors
$535,301Jun Qi · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Functional Networks for Persister Cell Sensitivities
$535,248Michael T McManus · University Of California, San Francisco · R01 · FY2019 · CA
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
$535,239Peter Karl Sorger · Harvard Medical School · U54 · FY2022 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
$535,071Eric T Ahrens · University Of California, San Diego · R01 · FY2018 · CA
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
$534,844Barry Jones · Arisaph Pharmaceuticals, Inc. · R42 · FY2014 · CA
Immunologic Monitoring and Cellular Products Laboratory
$534,844Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · P30 · FY2016 · CA
Imaging cellular assemblies with three-dimensional electron microscopy
$534,742Sriram Subramaniam · Basic Sciences · Z01 · FY2007 · CA
Immunomodulating Ruthenium Metal Complexes for Melanoma PhotodynamicTherapy
$534,709Sherri McFarland · University Of Texas Arlington · R01 · FY2020 · CA
Tumor Microenvironment in Cancer Progression
$534,706Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
RADIORECEPTOR GUIDED SURGERY OF NEURAL CREST TUMORS
$534,689University Of Iowa · R01 · FY2002 · CA
TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction
$534,677Mary Philip · Vanderbilt University Medical Center · R37 · FY2023 · CA
Defining mechanisms to promote antitumor immunity by modulating one-carbon metabolism
$534,622Arlene H Sharpe · Harvard Medical School · R01 · FY2024 · CA
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
$534,585Andrea Facciabene · University Of Pennsylvania · R01 · FY2019 · CA